VeinWay

Executive Summary

VeinWay is an Israeli med-tech company addressing a significant unmet need in venous disease: chronic venous occlusions that are difficult or impossible to cross with existing devices. Its flagship product, the Traversa system, is a nitinol-based catheter designed to safely and rapidly traverse such occlusions, potentially restoring blood flow and reducing complications like post-thrombotic syndrome. The company targets patients with deep vein thrombosis and chronic venous insufficiency, a large and underserved population. Currently at preclinical stage, VeinWay has the opportunity to differentiate itself in the peripheral vascular market, which is dominated by less effective mechanical crossing tools. If successful, Traversa could become a standard tool for interventional radiologists and vascular surgeons, addressing a critical procedural bottleneck and improving patient outcomes. The company's early-stage status implies high risk but also substantial upside if clinical validation is achieved.

Upcoming Catalysts (preview)

• Q4 2026First-in-human study initiation60% success
• 2027CE mark submission for Traversa system55% success
• Q2 2026Series A funding round closure70% success